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Whilst considered a routine procedure 
today, in vitro fertilization (IVF) still 
face huge opposition with cost 
consideration being an important 
impediment to its widespread 
acceptance. Various interventions to 
make IVF more patient friendly and 
cost- effective involve proper patients’ 
education, modifications in ovulation 
induction, egg retrieval, embryo 




The story of in vitro fertilization 
(IVF) has its beginning in 1973 with a 
lady, Doris Del-Zio, and her struggle to 
have a child.1 Desperate following 
multiple failed attempts to correct her 
blocked fallopian tubes, Del- Zio 
agreed to undergo an experimental 
procedure that had hitherto only been 
tested on lower mammals. Following 
surgical removal of a few eggs from 
her and fertilization of same on a glass 
test-tube with the resulting zygote 
cultured in a medium, the covert 
procedure was discovered and shut 
down by the boss of the eccentric 
researcher Landrum Shettle of the 
Columbia University. Shettles’ boss, 
Raymond Vande, did so for fear of the 
reputation of the school. The 
distraught Zio and her husband 
frustrated at this loss of opportunity 
sued.1 
The opportunity for the first successful 
IVF expectedly occurred in Europe as 
the prevalent thinking then across 
North America was that IVF would lead 
to genetic engineering and selective 
breeding, which would destroy the 
concept of humanity.1,2 The birth of 
Louise Brown on the 25th of July, 1978 
from the historic collaboration between 
Robert Edwards, a scientist from 
Cambridge, and Patrick Steptoe, a 
Gynaecologist in Lancashire, 
announced the first birth from IVF and 
heralded a new dawn in the 
management of infertility.1,3,4,5 The IVF 
was performed because Lesley Brown 
had no tubes (which had been 
removed from two previous ectopic) 
but had normal uterine cavity and was 
normally ovulating.4   
Since this landmark event, achieved 
from a natural cycle, the procedure of 
IVF has undergone several 
modifications with the aim of improving 
success rate (human reproduction 
itself being a notably wasteful 
process).3,4,5 While the basic principles 
of oocyte collection, extra-corporal 
fertilization and subsequent intra-
uterine transfer of the resulting embryo 
have remained the same,3 many 
modifications of the original technique 
has however been introduced over the 
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years to improve the result of 
treatment and patient acceptability of 
the procedure. These modifications 
have on the other hand resulted in an 
increased cost of the procedure and 
resultantly hampered patients’ 
acceptance and ability to undergo the 
procedure.  
Cost is a major obstacle for most 
patients.3,6 Treatment involves 
injections of expensive medications; 
monitoring ovarian response to 
medication with serum blood tests 
such as estradiol (E2), luteinizing 
hormone (LH), and progesterone (P4); 
monitoring follicular development with 
pelvic ultrasound examination; egg 
retrieval; fertilization of egg and the 
embryo culture; and, finally, embryo 
transfer. If any embryo remains after 
transfer is completed, there can be the 
additional cost of freezing and storing 
the spare embryos6,7. IVF is also 
physically and emotionally intense6. 
Hence, despite proven success and 
benefits, IVF remains unavailable to 
many.6 An ideal technique therefore 
would be one with a protocol that is 
highly effective and yet reduces 
expense and increases patients’ 
acceptance. Cost reduction is 
especially needed in a resource-limited 
setting.  
Despite these impediments, IVF clinics 
are found in almost every country 
worldwide6, and IVF is used to treat 
many aetiological factors in infertility 
including tubal diseases, male factor, 
endometriosis, and unexplained 
infertility3,5,6. With this increasing 
popularity, the need arises to explore 
ways of tackling cost and other 
impediment to patients’ acceptance of 
the procedure. This review attempts to 
highlight current standard protocol of 
IVF regimen while exploring some of 
the area where cost-saving and patient 
friendly modifications have been 
employed by workers in different 
settings. It is hoped that wider 
adaptation of some of these 
modifications would go a long way in 
making the process of IVF more 




Patient counselling is a vital part of 
initial and subsequent patient care. 
Patients are expected to master a lot 
of new information; they need to 
understand the steps involved in the 
process as well as learn how to 
administer injections. This typically 
may take upwards of an hour meeting6 
and may be more time-consuming for 
the semi-illiterate patients that may be 
seen in resource-limited settings. 
Many clinical settings have developed 
special multi-media education systems 
to provide IVF orientation. This 
typically involves video clips that last 
25-30 minutes, each programmed to 
meet each couples need. This 
multimedia education may be provided 
on group basis to patients on initial 
contact or in a ‘batch’ of selected 
patients. Further questions and 
individual concerns can then be taken 
privately to meet a couples’ particular 
need. The multimedia video clip has 
the unique advantage of ensuring 




One difficult task faced by patients on 
IVF treatment is learning to perform 
intramuscular (IM) injections required 
as part of IVF ovarian stimulation 
protocol. Although self-administration 
is possible, it is common to conscript a 
second partner, usually a spouse. 
Getting a willing party that will be 
available at all times to partake in 
injection administration can be a 
source of stress, as the party needs to 
be available at all times and needs to 
be trained in the technique of injection 
administration. To subvert this 
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problem, subcutaneous (SC) injection 
is increasingly being embraced 
because of ease of self-administration 
and easier tolerability. 
Controlled ovarian stimulation in IVF 
typically involves the use of 
gonadotropin releasing hormone 
agonists (GnRH-a) and follicle 
stimulating hormone (FSH). The 
GnRH-a is used to achieve pituitary 
down-regulation, prevent premature 
ovulation and stimulate the 
development of several mature follicles 
from the ovary and increase the 
chances of obtaining fertilisable 
eggs.3,4,6  Typically, twice daily 
injections may be required to be given. 
Reducing the number of injections 
from four to two or from two to one (by 
mixing the GnRH-a into prepared vial 
of FSH) has been found to reduce 
injection related anxiety of even the 
least ‘needle-phobic’ patient without 
causing any clinical difference in the 
number of eggs retrieved and fertilized 
or on the quality of embryos and 
pregnancy rates6 – although local 
reactions are commoner with SC 
injections compared to IM injections. 
Long protocols are still at present the 
most widely used protocols throughout 
the world5 and involve the use of a 
GnRH-a (taken on a daily basis nasally 
{e.g Buserelin, Naferelin}, or daily 
subcutaneous injections {e.g 
Buserelin, Leuprorelin} or in a depot 
preparation {Goserelin, Leuprorelin}) to 
achieve pituitary down-regulation 
before administration of 
gonadotrophins. Typically pituitary 
desensitization using GnRH-a is 
commenced between days 19 and 22 
of the preceding cycle (rationale being 
to create a temporary menopause from 
which the ovaries can be stimulated by 
use of FSH/hMG). Following 
confirmation of adequate suppression 
(by TVS and/ or serum estradiol 
measurement), done usually 7-10days 
after initiation of GnRH-a, the 
gonadotrophins are started until 
adequate ovarian response- presence 
of 2 or more follicles ≥ 18mm. 
 Short (flare) protocols have also been 
developed and may be agonist or 
antagonist protocols. The short agonist 
protocol involves starting GnRH-a on 
day 2 and FSH/hMG on day 3of the 
menstrual cycle and is used for those 
whom difficulty with ovarian stimulation 
is anticipated- those ≥40years, those 
with high initial FSH levels and those 
with prior failure with the long protocol. 
More recently, a more patient friendly 
GnRH antagonist protocol (using 
Ganirelix and Cetrorelix) has been 
introduced.3,5,6 The antagonist has an 
almost immediate effect on the 
pituitary and does not need several 
days to achieve menopausal levels 
that agonists do. A daily SC injection 
of 0.25mg Cetrolelix is normally given, 
although there is a 3mg dose whose 
effect can last for several days. This  is 
commenced on first day of FSH/hMG 
stimulation (usually starting from the 
fifth day or when the lead follicle is a 
certain size on USS {14mm} and 
continued alongside the FSH/hMG 
stimulation until adequate response 
and then stopped prior to hCG 
injection. The benefits of antagonists 
over agonists include no menopausal 
side effects, no cyst formation from 
initial gonadotrophin surge, shorter 
cycle duration, less gonadotrophin 
required per cycle5- and therefore 
lower drug cost! To circumvent high 
cost of drugs and promote patient 
convenience, there is a place for the 
use of other treatment protocols to 
achieve superovulation while avoiding 
the disadvantage of early Luteinizing 
Hormone (LH) surge. One such 
protocol is the low cost Clomiphene 
Citrate/Human Menopausal 
Gonadotrophin (hMG) protocol which 
has been noted to achieve similar 
clinical pregnancy rates as the 
standard Buserelin/hMG protocol.8 
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Use of clomiphene citrate instead of 
FSH for ovarian stimulation 
significantly reduces cost, significantly 
reduces the duration of treatment, 
produces satisfactory pregnancy rates 
and reduces the number of injections a 
patient receives.8  
There is also the stop protocol wherein 
the GnRH-a is stopped on start of 
hMG administration.  
Following the GnRH-a and FSH 
administration ovulation is triggered by 
administration of 10,000iu human 
chorionic gonadotrophin (hCG) 
(5,000iu for those at risk of ovarian 
hyperstimulation syndrome {OHSS}) 
when two or more follicles measuring 
18-20mm in diameter is noted.  
 
Egg Retrieval: 
Retrieval of oocytes during IVF is 
uncomfortable. Various ways of 
inducing analgesia and anaesthesia 
have been described, including 
general anaesthesia, oral narcotics, 
paracervical block and regional 
anaesthesia. Paracervical block, as 
employed in our setting, and use of 
short acting general anaesthetic 
agents may be ideal as they enhances 
full recovery and allows for quicker 
discharge patients.   
Oocyte retrieval was done 
laparoscopically in the past but the 
advent of real-time USS has allowed a 
less invasive USS-directed needling of 
the ovaries. The laparoscope is 
occasionally used if the ovaries are 
inaccessible transvaginally. 
The follicular aspiration is scheduled 
for 34-36 hours after hCG injection 
prior to physiological ovulation 
occurring. If hCG is incorrectly 
administered, few or no eggs are 
obtained at egg collection itself. 
Eggs are fertilized either by routine 
insemination of approximately 50,000 
to 100,000 normally motile sperm or by 
ICSI. 
 
Embryo Incubation:  
The process of embryo incubation is 
an exacting one that requires the 
services of an embryologist. A variety 
of media have been used with success 
for embryo culture. Electrolyte 
concentrations are usually adjusted to 
simulate the levels in a normal human 
Fallopian tube. Not only is the 
temperature carefully controlled in the 
incubator, but also the gas content and 
pH.7  
It is unfortunate that many centres in 
our setting still rely on the services of 
foreign embryologists to handle the 
laboratory aspects of IVF rather than 
focus on training (formal or on-hands) 
of local staffs. The cost of catering for 
these foreign personnel adds 
significantly to the high cost of IVF and 
centres in our setting may do well in 
embarking on training of selected 
staffs in particular aspects of 
embryology. 
 
Post embryo Transfer: 
There is no evidence to support the 
varied instructions given to patient that 
have undergone IVF post-embryo 
transfer; there is perhaps more myth in 
these than in any other aspect of IVF. 
Some programmes require patients to 
remain on strict bed-rest for nearly 2 
weeks from embryo transfer until 
pregnancy test, even when there are 
no data to support such restriction. 
Because many patients may be 
anxious and express caution, it may be 
ideal to allow the patients to rest for 
anywhere up to 2 hours, if anything, to 
act as a source of psychological 
support. 
 
Luteal Phase Support: 
Whilst pregnancies resulting from 
natural IVF cycles do not require luteal 
phase supplementation, with the use 
of HMG/GnRH-a or GnRH- antagonist 
it is necessary to support the luteal 
phase with hCG or progesterone the 
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basis being that super-ovulation may 
impair normal corpus luteal function.5 
Use of hCG for luteal support is 
associated with a higher risk of ovarian 
hyperstimulation than progesterone. 
Progesterone has the added 
advantage of coming in different 
formulations (tablets, injections, 
vaginal pessaries and rectal 
suppositories) and this may further 
optimize patients’ satisfaction. 
 
CONCLUSION 
Over the last 25 year the success rate 
and types of IVF have greatly 
improved and at present there are well 
over 2 million babies born throughout 
the world by this technique.5 However, 
only a very small percentage of 
patients that require this form of 
‘terminal care’ are able to access it. 
Unlike in the past when opposition to 
the then novel concept by different 
strata of society9 had defined 
acceptance, presently major 
impediment to acceptance and access 
to IVF are the cost of treatment and 
patients’ satisfaction. Practicable 
measures to optimize these at different 
levels of the IVF process have been 
highlighted. Cost consideration is 
especially important in resource- 
limited settings where, though infertility 
is widespread and a serious concern 
especially to the woman leading on to 
marital disharmony, neglect, abuse, 
loss of social security, polygamy and 
even suicide,4 the case that had been 
made for a redirecting of attention by 
assisted conception practitioners, from 
IVF to the preventive aspects of 
infertility management on the fear that 
extending infertility treatment to 
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